Clinical Data Revolution rises 40% as pancreatic cancer drug doubles survival BioSpaceIn a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival.Clinical DataOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) BioSpace In a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival. Clinical DataOncologyRead full story Post navigation Previous: IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacyNext: 220: An Interview With Dr. Jaime Moore on Obesity Medications and Neuromuscular Disease Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
